Publications
381 results found
Padayachee Y, Cafferkey J, Park M, et al., 2021, NEGATIVE INTERFERON-GAMMA RELEASE ASSAYS RELIABLY RULE OUT PROGRESSION TO ACTIVE TB IN PATIENTS WHO HAVE INFLAMMATORY CONDITIONS AND ARE STARTING BIOLOGIC THERAPY, Publisher: BMJ PUBLISHING GROUP, Pages: A54-A54, ISSN: 0040-6376
Owles HLB, Padmanaban V, Thacker M, et al., 2021, FEASIBILITY AND USAGE OF ONE MINUTE SIT-TO-STAND TEST, AS A MEASURE OF RECOVERY IN POST-ACUTE COVID 19 PATIENTS, FOLLOWING HOSPITAL DISCHARGE, Publisher: BMJ PUBLISHING GROUP, Pages: A35-A35, ISSN: 0040-6376
Puranik S, Harlow C, Park M, et al., 2021, MONITORING PROLONGATION OF QT INTERVAL IN PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIUM USING MOBILE HEALTH DEVICE ALIVECOR, Publisher: BMJ PUBLISHING GROUP, Pages: A175-A176, ISSN: 0040-6376
- Author Web Link
- Cite
- Citations: 2
Manalan K, Park M, Ratnayake C, et al., 2021, A LONDON CENTRE BASED REVIEW OF TUBERCULOSIS POST KIDNEY TRANSPLANTATION, Publisher: BMJ PUBLISHING GROUP, Pages: A173-A174, ISSN: 0040-6376
Park M, Padayachee Y, Ryan L, et al., 2021, MULTIDRUG RESISTANT TUBERCULOSIS - PATIENTS' PERSPECTIVE AND EXPERIENCES IN A LONDON TB CENTRE, Publisher: BMJ PUBLISHING GROUP, Pages: A174-A174, ISSN: 0040-6376
Park M, Kon OM, 2021, Use of Xpert MTB/RIF and Xpert Ultra in extrapulmonary tuberculosis, EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, Vol: 19, Pages: 65-77, ISSN: 1478-7210
- Author Web Link
- Cite
- Citations: 20
Manalan K, Barrett J, Kon OM, 2021, Tuberculosis Clinical Presentation and Differential Diagnosis, Essential Tuberculosis, Pages: 79-85, ISBN: 9783030667054
Active tuberculosis (TB) disease presents with a variety of symptoms and signs. Mycobacterium tuberculosis (MTB) can affect multiple organs; within this chapter we review common symptoms and signs of active TB in the lung and extra-pulmonary sites. The sites of disease explored include: pulmonary infections, lymph node disease and central nervous system disease amongst others. Possible differential diagnoses to be considered are discussed within each organ, though often there may be overlap in the clinical presentations. Individuals may have localised presentations for example with abdominal or musculoskeletal disease with or without constitutional symptoms. Sometimes localised TB may precede systemic infection or be the only manifestation of active disease, for example ocular and cutaneous TB, and the spectrum of clinical manifestations are described which should prompt a clinician to investigate further. Atypical infection in those with underlying immunosuppression is also explored within this chapter.
Meghji J, Kon OM, 2021, TB Treatment Complications, Tuberculosis in Clinical Practice, Pages: 263-278, ISBN: 9783030755089
The aims of TB drug treatment are to rapidly reduce bacillary load to achieve clinical improvement, to remove persistor organisms to prevent relapse, to avoid drug resistance. Stard first-line treatment for drug sensitive PTB EPTB disease in both HIV-positive -negative adults requires quadruple therapy with RIF, INH, PZA ETH. Drug therapy is typically provided for 6-months (2 RHZE/4 RH) with extension of the continuation phase in the treatment of TB meningitis, ocular TB disease, possibly in those with a high initial bacillary load. Adjunctive treatments including pyridoxine (all patients), corticosteroids (TB meningitis) may be required. Drugs can be provided individually or in fixed-dose preparations, but practitioners must be aware of common/severe side effects of these medications. Treatment programmes must have capacity for pre-treatment assessment of patient risk, monitoring of patients during treatment, management of complications.
Park M, Ross C, Kon OM, 2021, Pulmonary, Pleural Mediastinal TB: Clinical Aspects Diagnosis, Tuberculosis in Clinical Practice, Pages: 29-52, ISBN: 9783030755089
In this chapter we discuss pulmonary, pleural mediastinal TB. We review the common presenting clinical radiological features of these. Diagnostic approaches for each are explored incorporate currently available interventional molecular tools.
Kon OM, 2021, Tuberculosis in Clinical Practice, ISBN: 9783030755089
This book is targeted at ensuring frontline clinical staff including seniors, trainees specialist nurses can easily reference the optimum investigation management of potential TB cases. This will mirror the annual London Advanced TB course which aims to equip all of the team delivering care to have a working knowledge of the entire spectrum of the real life aspects of TB management ranging from investigation of active TB to latent screening in pre biologic therapy. It includes an update of MDR TB management also the approaches needed to ensure the entire medico-social spectrum of TB care is addressed.
Agrawal R, Testi I, Rousselot A, et al., 2021, Insights into the molecular pathogenesis of ocular tuberculosis, TUBERCULOSIS, Vol: 126, ISSN: 1472-9792
- Author Web Link
- Cite
- Citations: 7
Dhawan RT, Gopalan D, Howard L, et al., 2021, Beyond the clot: perfusion imaging of the pulmonary vasculature after COVID-19, LANCET RESPIRATORY MEDICINE, Vol: 9, Pages: 107-116, ISSN: 2213-2600
- Author Web Link
- Cite
- Citations: 92
Park M, Dhawan R, Whittaker E, et al., 2021, CA 125 and TB, BMJ CASE REPORTS, Vol: 14
- Author Web Link
- Cite
- Citations: 4
Zhu J, Mallia P, Footitt J, et al., 2020, Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD, Journal of Allergy and Clinical Immunology, Vol: 146, Pages: 840-850.e7, ISSN: 0091-6749
BackgroundRespiratory viral infection causes chronic obstructive pulmonary disease (COPD) exacerbations. We previously reported increased bronchial mucosa eosinophil and neutrophil inflammation in patients with COPD experiencing naturally occurring exacerbations. But it is unclear whether virus per se induces bronchial mucosal inflammation, nor whether this relates to exacerbation severity.ObjectivesWe sought to determine the extent and nature of bronchial mucosal inflammation following experimental rhinovirus (RV)-16–induced COPD exacerbations and its relationship to disease severity.MethodsBronchial mucosal inflammatory cell phenotypes were determined at preinfection baseline and following experimental RV infection in 17 Global Initiative for Chronic Obstructive Lung Disease stage II subjects with COPD and as controls 20 smokers and 11 nonsmokers with normal lung function. No subject had a history of asthma/allergic rhinitis: all had negative results for aeroallergen skin prick tests.ResultsRV infection increased the numbers of bronchial mucosal eosinophils and neutrophils only in COPD and CD8+ T lymphocytes in patients with COPD and nonsmokers. Monocytes/macrophages, CD4+ T lymphocytes, and CD20+ B lymphocytes were increased in all subjects. At baseline, compared with nonsmokers, subjects with COPD and smokers had increased numbers of bronchial mucosal monocytes/macrophages and CD8+ T lymphocytes but fewer numbers of CD4+ T lymphocytes and CD20+ B lymphocytes. The virus-induced inflammatory cells in patients with COPD were positively associated with virus load, illness severity, and reductions in lung function.ConclusionsExperimental RV infection induces bronchial mucosal eosinophilia and neutrophilia only in patients with COPD and monocytes/macrophages and lymphocytes in both patients with COPD and control subjects. The virus-induced inflammatory cell phenotypes observed in COPD positively related to virus load and illness severity. Antiviral/anti-inflamma
Harlow CF, Meghji J, Martin L, et al., 2020, Republished: Rifampicin induced shock during re-exposure for treatment of latent tuberculosis., Drug Ther Bull, Vol: 58, Pages: 157-159
Testi I, Agrawal R, Mahajan S, et al., 2020, Tubercular Uveitis: Nuggets from Collaborative Ocular Tuberculosis Study (COTS)-1, OCULAR IMMUNOLOGY AND INFLAMMATION, Vol: 28, Pages: 8-16, ISSN: 0927-3948
- Author Web Link
- Cite
- Citations: 19
Agrawal R, Betzler BK, Testi I, et al., 2020, The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 447 Patients with Tubercular Intermediate Uveitis and Panuveitis, OCULAR IMMUNOLOGY AND INFLAMMATION, Vol: 28, Pages: 27-37, ISSN: 0927-3948
- Author Web Link
- Cite
- Citations: 6
Agrawal R, Gunasekeran DV, Agarwal A, et al., 2020, Visual Morbidity in Ocular Tuberculosis - Collaborative Ocular Tuberculosis Study (COTS)-1: Report #6, OCULAR IMMUNOLOGY AND INFLAMMATION, Vol: 28, Pages: 49-57, ISSN: 0927-3948
- Author Web Link
- Cite
- Citations: 2
Testi I, Agrawal R, Mahajan S, et al., 2020, The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Descriptive Review of Tubercular Uveitis in Paediatric Population, OCULAR IMMUNOLOGY AND INFLAMMATION, Vol: 28, Pages: 58-64, ISSN: 0927-3948
- Author Web Link
- Cite
- Citations: 4
Agarwal A, Agrawal R, Raje D, et al., 2020, Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the "Cure" in Ocular Tuberculosis, OCULAR IMMUNOLOGY AND INFLAMMATION, Vol: 28, Pages: 65-73, ISSN: 0927-3948
- Author Web Link
- Cite
- Citations: 10
Agrawal R, Betzler B, Testi I, et al., 2020, The Collaborative Ocular Tuberculosis Study (COTS)-1: A Multinational Review of 165 Patients with Tubercular Anterior Uveitis, OCULAR IMMUNOLOGY AND INFLAMMATION, Vol: 28, Pages: 17-26, ISSN: 0927-3948
- Author Web Link
- Cite
- Citations: 6
Agrawal R, Testi I, Mahajan S, et al., 2020, The Collaborative Ocular Tuberculosis Study (COTS) Consensus (CON) Group Meeting Proceedings, OCULAR IMMUNOLOGY AND INFLAMMATION, Vol: 28, Pages: 85-95, ISSN: 0927-3948
- Author Web Link
- Cite
- Citations: 18
Park M, Owles H, Williams A, et al., 2020, PEDIATRIC ENDOBRONCHIAL ULTRASOUNDTRANSBRONCHIALNEEDLE ASPIRATION UNDERCONSCIOUS SEDATION FOR SUSPECTEDTUBERCULOSIS IN LONDON, Paediatric infectious diseases journal
Manalan K, Green N, Arnold A, et al., 2020, A UK cost comparison of amikacin therapy with bedaquiline, for drug resistant tuberculosis, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Cafferkey J, Kostich S, Jewell P, et al., 2020, TB following targeted and biological therapy: can we predict it?, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Park M, Kumar K, O'Riordan S, et al., 2020, Diagnostic accuracy of TB PCR in mediastinal lymph node TB in a UK centre using EBUS-TBNA, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Manalan K, Park M, Ratnayake C, et al., 2020, A UK centre based review of tuberculosis post kidney transplantation, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 0903-1936
Meghji J, Kon OM, 2020, Opportunistic mycobacterial diseases, Medicine (United Kingdom), Vol: 48, Pages: 363-365, ISSN: 1357-3039
Non-tuberculous mycobacteria (NTM) are hardy environmental organisms: >200 species have been identified, with highly variable pathogenicity. NTM infection is usually acquired from the environment and can be asymptomatic or associated with pulmonary disease (NTM-PD), particularly in patients with immunocompromise, chronic lung conditions or impaired mucociliary clearance. The incidence of NTM isolates and NTM-PD is rising in resource-rich settings. Diagnosis of NTM-PD requires both positive microbiology and typical clinical and radiological features. Treatment typically requires multidrug therapy for at least 12 months, with a combination of oral, nebulized and intravenous antibiotics depending on the NTM species, severity of disease, drug resistance patterns and treatment response. Surgery can be used for localized refractory disease. Outcomes are highly variable and cure may not be possible. Disease should be managed in specialized multidisciplinary team settings where possible.
Ainley A, Kon OM, 2020, Clinical tuberculosis, Medicine (United Kingdom), Vol: 48, Pages: 356-362, ISSN: 1357-3039
In 1993 the World Health Organization declared tuberculosis (TB) a global public health emergency, and yet 26 years later it remains a significant public health issue globally and nationally within the UK. Although the overall incidence and mortality have improved, there remains considerable work to tackle both an underserved population who present unique and complex challenges, and the continuing threat from drug resistance. Within the UK and worldwide, numerous stakeholders have established networks, guidance and frameworks to facilitate a more targeted and standardized approach to the detection, diagnosis and management of patients. Furthermore, novel diagnostic tools and treatments aim to reduce the burden of disease, with the ultimate aim of eradicating TB.
Farne H, Glanville N, Johnson N, et al., 2020, The CRTH2 Antagonist Timapiprant Does Not Alter the Response Rhinovirus Infection in Asthma: A Randomized, Placebo-Controlled Trial, International Conference of the American-Thoracic-Society, Publisher: AMER THORACIC SOC, ISSN: 1073-449X
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.